TrialThe oncologist2020

A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.

Zhong-Zhe Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.